ArticleBMC psychiatry2019
Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice.
Article in BMC psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Impact of medication side effects on medication adherence and implications for treatment outcomes in patients with borderline personality disorder: a pilot study.BMC psychiatry · 2026Article
- Efficacy of Guanfacine for Self-injurious and Aggressive Behaviors through the Reduction of Impulsivity in Borderline Personality Disorder: Two Case Reports and a Literature Review.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025Article
- Evaluation of Adherence to Pharmacological Treatment in a Large Sample of Patients with Personality Disorder.Clinical neuropsychiatry · 2025Article
- Cluster B personality disorders and psychotropic medications: a focused analysis of trends and patterns across sex and age groups.Social psychiatry and psychiatric epidemiology · 2025Article
- Gender bias of antisocial and borderline personality disorders among psychiatrists.Archives of women's mental health · 2025Article
- Comparative Effectiveness of Pharmacotherapies for the Risk of Attempted or Completed Suicide Among Persons With Borderline Personality Disorder.JAMA network open · 2023Article
- Overdose and off-label psychotropic prescribing in patients with borderline personality disorder: A retrospective series.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists · 2023Observational
- Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain.Journal of fungi (Basel, Switzerland) · 2022Review
- The State of Overmedication in Borderline Personality Disorder: Interpersonal and Structural Factors.Current treatment options in psychiatry · 2022Article
- From contact coverage to effective coverage of community care for patients with severe mental disorders: A real-world investigation from Italy.Frontiers in psychiatry · 2022Article
- Factors associated with pharmacological and psychotherapy treatments adherence in patients with borderline personality disorder.Frontiers in psychiatry · 2022Article
- Antipsychotic-Related Stigma and the Impact on Treatment Choices: A Systematic Review and Framework Synthesis.Patient preference and adherence · 2022Review
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this study was to assess the pharmacological treatment strategies of inpatients with borderline personality disorder between 2008 and 2012. Additionally, we compared pharmacotherapy during this period to a previous one (1996 to 2004).
methodsCharts of 87 patients with the main diagnosis of borderline personality disorder receiving inpatient treatment in the University Medical Center of Goettingen, Germany, between 2008 and 2012 were evaluated retrospectively. For each inpatient treatment, psychotropic drug therapy including admission and discharge medication was documented. We compared the prescription rates of the interval 2008-2012 with the interval 1996-2004.
results94% of all inpatients of the interval 2008-2012 were treated with at least one psychotropic drug at time of discharge. All classes of psychotropic drugs were applied. We found high prescription rates of naltrexone (35.6%), quetiapine (19.5%), mirtazapine (18.4%), sertraline (12.6%), and escitalopram (11.5%). Compared to 1996-2004, rates of low-potency antipsychotics, tri-/tetracyclic antidepressants and mood stabilizers significantly decreased while usage of naltrexone significantly increased.
conclusionsIn inpatient settings, pharmacotherapy is still highly prevalent in the management of BPD. Prescription strategies changed between 1996 and 2012. Quetiapine was preferred, older antidepressants and low-potency antipsychotics were avoided. Opioid antagonists are increasingly used and should be considered for further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.